具体内容详见公司在巨潮资讯网披露的《2024 年第一季度报告》。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 二、审议《关于会计政策变更的议案》 证券代码：300244 证券简称：迪安诊断 公告编号：2024-036 迪安诊断技术集团股份有限公司 第五届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2024 年 4 月 26 日上午 10 点，迪安诊断技术集团股份有限公司（以下简称 "公司"或"迪安诊断"）以通讯表决方式召开了第五届董事会第六次会议。会 议通知已于 2024 年 4 月 23 日以短信、电子邮件等方式通知全体董事。本次会议 由公司董事长陈海斌先生召集和主持。本次会议应出席董事 9 人，实际出席董事 9 人，符合《公司法》《证券法》和《公司章程》的有关规定。会议通过了如下 决议： 一、审议《关于<2024 年第一季度报告>的议案》 1 本次会计政策变更是公司根据国家财政部相关文件要求进行的合理变更，符 合《企业会计准则》等相关规定及公司实际情况，能够更加客观、公允地反映公 司的财务状况和经营成果，不会对公司当 ...

证券代码：300244 证券简称：迪安诊断 公告编号：2024-035 迪安诊断技术集团股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 本次会计政策变更是公司根据中华人民共和国财政部（以下简称"财政部"） 相关规定进行的变更，不会对公司财务状况、经营成果和现金流量产生重大影响。 2024 年 4 月 26 日，公司召开第五届董事会第六次会议和第五届监事会第四 次会议，审议通过了《关于会计政策变更的议案》，本次会计政策变更无需提交 股东大会，现将相关事宜公告如下： 一、会计政策变更概述 (二)变更前采用的会计政策 本次会计政策变更前，公司执行财政部颁布的《企业会计准则——基本准则》 和各项具体会计准则、企业会计准则应用指南、企业会计准则解释公告及其他相 关规定。 (一)会计政策变更的原因及时间 财政部于 2023 年 10 月 25 日公布了《企业会计准则解释第 17 号》（财会 〔2023〕21 号），规定了"关于流动负债与非流动负债的划分"、"关于供应商 融资安排的披露"、"关于售后租回交易的会计处理"，上述 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 20.00 CNY per share [3][14]. Core Insights - The company has shown a significant improvement in operating cash flow, with a net cash flow from operating activities of 1.921 billion CNY in 2023, an increase of 17.20% year-on-year [13]. - The conventional diagnostic services have demonstrated steady growth, with the diagnostic services segment generating revenue of 5.187 billion CNY in 2023, reflecting a year-on-year growth of 11.91% when excluding COVID-19 impacts [13]. - The company is expanding its business both domestically and internationally, with new projects and partnerships contributing to revenue growth [13]. Financial Summary - **Revenue**: The company reported revenue of 13.408 billion CNY in 2023, a decrease of 33.9% compared to 2022. Projections for 2024, 2025, and 2026 are 15.039 billion CNY, 16.925 billion CNY, and 19.106 billion CNY, respectively, indicating a recovery trend with expected growth rates of 12.2%, 12.5%, and 12.9% [2]. - **Net Profit**: The net profit attributable to the parent company was 307 million CNY in 2023, down 78.6% from 2022. Forecasts for the next three years are 785 million CNY, 989 million CNY, and 1.246 billion CNY, with significant growth expected in 2024 at 155.4% [2]. - **Earnings Per Share (EPS)**: The EPS for 2023 was 0.49 CNY, with projections of 1.25 CNY, 1.58 CNY, and 1.99 CNY for 2024, 2025, and 2026, respectively [2][14]. - **Profit Margins**: The gross margin for 2023 was 31.3%, with projections of 32.3%, 32.8%, and 33.3% for the following years [2]. The net margin was 2.3% in 2023, expected to improve to 5.2%, 5.8%, and 6.5% in the next three years [2]. Business Development - The company has launched 1,023 new testing projects and increased the number of tier-three hospital clients by 238, with tier-three hospital revenue accounting for 32.8% of total revenue [13]. - The company is also expanding its international presence, with plans to establish its first overseas ICL laboratory in Vietnam [13].

评级标准 [Table_ReportType] 公司点评 （一）公司财务预测表 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |---------------------------------------------------------------------|-------|-------|----------------------------------------------|-------|--------------------------------------------------------------------------------|---------|---------|-------------------------------------|---------| | [ 资产负债表（百万元） Table_Money] | 2023A | | 2024E 2025E | | 2026E 利润表（百万元） 2023A 2024E 2025E 2026E | | | | | | 流动资产 13815. ...

ICL 业务延续良好增长，经营性现金流持续改善 | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------- ...

| --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - Total assets of Hangzhou Dian Diagnostics reached CNY 8,144,514,711.30, with net assets attributable to the parent company at CNY 3,148,982,457.11 as of December 31, 2023[8]. - Hangzhou Dian achieved operating revenue of CNY 5,149,026,068.90, with an operating profit of CNY 191,131,541.38 and a net profit attributable to the parent company of CNY 106,998,915.85 during the reporting period[8]. - Beijing United Zhixin Medical Technology reported total assets of CNY 1,047,227,337.90 and net assets attributable to the parent company of CNY 652,661,688.69 as of December 31, 2023[9]. - Operating revenue for Beijing United Zhixin was CNY 1,037,203,032.30, with an operating profit of CNY 201,915,188.85 and a net profit attributable to the parent company of CNY 128,072,781.98[9]. - Qingdao Zhiying Medical Technology's total assets amounted to CNY 1,486,877,560.96, with net assets attributable to the parent company at CNY 944,877,879.25 as of December 31, 2023[13]. - The company reported operating revenue of CNY 1,553,391,719.19, with an operating profit of CNY 118,245,819.51 and a net profit attributable to the parent company of CNY 87,069,869.01 during the reporting period[13]. - Guangzhou Dihui Medical Device achieved total assets of CNY 1,148,238,169.25 and net assets attributable to the parent company of CNY 826,197,255.71 as of December 31, 2023[13]. - The operating revenue for Guangzhou Dihui was CNY 1,134,185,387.51, with an operating profit of CNY 124,470,407.76 and a net profit attributable to the parent company of CNY 88,429,305.98[13]. - The company reported a significant decline in net profit for the third quarter of 2023, with a loss of ¥223,417,843.36[116]. - The net profit attributable to shareholders for 2023 was ¥307,461,061.38, down 78.56% from ¥1,434,191,144.16 in 2022[115]. - The basic earnings per share for 2023 was ¥0.4918, a decline of 78.64% compared to ¥2.3022 in 2022[115]. - The total assets at the end of 2023 were ¥17,939,311,256.63, a decrease of 14.80% from ¥21,055,969,393.06 at the end of 2022[115]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year, representing a 20% year-over-year growth[95]. - The company reported a revenue of 1.2 billion RMB for the fiscal year 2023, representing a year-over-year growth of 15%[81]. Strategic Initiatives - The company has established several new subsidiaries, including Chengdu Dianrongkang Medical Device and Dian Diagnostics Vietnam Company Limited, which are expected to enhance market presence[5][7]. - The company continues to focus on expanding its market through strategic acquisitions and new product development initiatives[5][7]. - The company launched a five-year strategic plan in 2020, positioning itself as a provider of integrated medical diagnostic solutions, focusing on technological and business model innovations[14]. - In 2024, the company aims to enhance operational quality and profitability through strategic business deepening, particularly in precision centers and collaborative models, while targeting key projects in hematology, pathogen molecules, and neuroimmunology[18]. - The company plans to increase R&D investment, focusing on LDT, IVD, and digital intelligence, to expand its product line and enhance core competitiveness[18]. - The company is focusing on building a digital organization and improving customer experience through digitalization initiatives[38]. - The company aims to enhance its customer relationship management (CRM) system to improve user engagement and retention[81]. - The company is exploring potential acquisitions to bolster its service offerings, with a budget of 500 million RMB set aside for this purpose[95]. - The company is actively participating in the reform of the Chinese medical system, leveraging its strong R&D capabilities and flexible service models[179]. Market Expansion - The first overseas laboratory has been established in Vietnam, marking the company's entry into the Southeast Asian market, with plans to expand into Malaysia, Hong Kong, Thailand, Indonesia, Saudi Arabia, and the UAE[19]. - The company aims to enhance its international presence, with its subsidiary expanding laboratory services to multiple countries and officially opening a laboratory in Vietnam[38]. - The company is expanding its market presence in Southeast Asia, aiming for a 25% market share by 2025[81]. - The company plans to leverage its operational base in Urumqi to expand its business into Central Asia and the Middle East[38]. - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the call[66]. Research and Development - The company has achieved a 100% inclusion rate of its assets and revenues in the internal control evaluation scope, indicating comprehensive coverage[159]. - The company has completed the development of a multi-pathogen detection kit (Dano-seq V3.0) using nanopore sequencing, which aims to provide rapid and accurate pathogen detection results for common clinical pathogens[196]. - The company is currently developing a molecular POCT system for tuberculosis and non-tuberculous mycobacterium nucleic acid detection, targeting rapid on-site analysis to meet clinical needs[196]. - Ongoing research and development efforts are focused on enhancing existing technologies, with an investment of 100 million RMB allocated for the upcoming year[95]. - Research and development investment increased by 18%, focusing on innovative testing technologies[81]. - The company has successfully completed the development of a digital transaction project to enhance order management efficiency, aiming for full group rollout in 2024[200]. - The company has launched a clinical big data platform project, collaborating with 7 hospitals to provide integrated solutions for clinical data management and analysis[200]. - The company has completed the development of a multi-color digital PCR technology platform, which will expand its special testing product line for clinical services[200]. - The company is focusing on expanding its product line in tuberculosis testing to improve early screening and diagnosis, which is expected to boost performance[196]. - The company aims to establish a high-sensitivity detection system for drug-resistant diagnosis, enhancing its core competitiveness in the market[196]. Governance and Compliance - The company has established a governance system to ensure scientific decision-making and risk prevention, including the formation of a board advisory committee and various management teams[32]. - The company has a governance structure that complies with relevant laws and regulations, ensuring independent operation of the board and supervisory committee[60]. - The company has a total of 9 board members, including 3 independent directors, ensuring compliance with governance requirements[56]. - The company has established an internal audit system to oversee the authenticity and completeness of financial information[57]. - The company has established a risk management committee to strengthen quality culture and ensure compliance across all business segments[33]. - The company is committed to balancing the interests of shareholders, employees, and society, promoting sustainable and healthy development[57]. - The company has not reported any discrepancies between net profit and net assets under domestic and overseas accounting standards[147]. - The company has not reported any dissenting opinions from board members on significant matters during the reporting period[107]. - The company has maintained normal performance in fulfilling its commitments related to share transfer and related party transactions[171]. Human Resources - The total number of employees at the end of the reporting period was 10,843, with 4,732 being technical staff[125]. - The company has established six training bases across major cities in China to enhance employee skills, focusing on a "one-three-five-seven" talent development system[130]. - The company has optimized the "Qingzhu 2.0 Training Project" and the "One-Three-Five-Seven Talent Development System" to guide employee career development effectively[134]. - The company has a clear strategy for talent acquisition and retention, recognizing the importance of skilled professionals in maintaining innovation and growth[49]. - The company implemented a comprehensive compensation strategy based on position, performance, and capability, ensuring a competitive salary system to motivate employees[129]. Risks and Challenges - The company acknowledges potential risks related to diagnostic service quality, management, and regulatory compliance as it navigates the evolving healthcare landscape[20]. - The company is in a rapid growth phase, but increasing competition and new business models may lead to longer customer settlement cycles and increased accounts receivable, posing a risk of bad debts[50]. - The company is enhancing accounts receivable management by establishing a tracking mechanism and strengthening customer credit assessments to reduce the risk of bad debts[50]. - The company has not identified any significant or important deficiencies in its financial reporting controls during the self-inspection conducted in 2023[143]. Corporate Social Responsibility - The company is not classified as a key pollutant discharge unit and has not faced any penalties related to environmental protection laws during the reporting period[163]. - The company has not disclosed any measures taken to reduce carbon emissions during the reporting period[163]. - The company has not engaged in any activities related to poverty alleviation or rural revitalization during the reporting period[165]. - The company is actively involved in addressing corruption in the medical field, contributing to a healthier industry environment[184].

证券代码：300244 证券简称：迪安诊断 公告编号：2024-026 迪安诊断技术集团股份有限公司 关于拟续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2024 年 4 月 18 日，迪安诊断技术集团股份有限公司(以下简称"公司")召 开第五届董事会第五次会议、第五届监事会第三次会议，审议通过了《关于续聘 会计师事务所的议案》，拟续聘立信会计师事务所（特殊普通合伙）（以下简称"立 信会计师事务所"或"立信"）为公司 2024 年度审计机构。本议案尚需提交公司 股东大会审议，现将有关事项公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、基本信息 （5）执行事务合伙人：杨志国、朱建弟 截至 2023 年末，立信拥有合伙人 278 名、注册会计师 2,533 名、从业人员 总数 10,730 名、签署过证券服务业务审计报告的注册会计师 693 名。 立信 2023 年业务收入（经审计）50.01 亿元，其中审计业务收入 35.16 亿元， 证券业务收入 17.65 亿元。 2023 年度立信为 671 家上市公司提供年报审 ...

（一）日常关联交易概述 根据 2023 年迪安诊断技术集团股份有限公司（以下简称"迪安诊断"或 "公司"）关联交易的实际情况，并结合公司业务发展的需要，预计公司 2024 年与关联人发生日常关联交易总额不超过 11,371.82 万元。2023 年公司与关联人 发生的日常关联交易金额为 8,116.93 万元。 证券代码：300244 证券简称：迪安诊断 公告编号：2024-029 迪安诊断技术集团股份有限公司 关于 2024 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 2024 年 4 月 18 日，公司第五届董事会第五次会议以 6 票同意、0 票反对、 0 票弃权，审议通过了《关于 2024 年度日常关联交易预计的议案》，关联董事陈 海斌、叶小平、俞德超回避表决。 本次日常关联交易事项尚需提交 2023 年年度股东大会审议，关联股东陈海 斌须回避表决。 （二）预计日常关联交易类别和金额 公司 2024 年度拟与关联人发生日常关联交易金额不超过 11,371.82 万元，具 体内容如下： 单位：万元 ...

本人作为迪安诊断技术集团股份有限公司（以下简称"公司"）的独立董事， 在任职期间严格按照《公司法》《证券法》《上市公司独立董事规则》《深圳证券 交易所上市公司自律监管指引第2号——创业板上市公司规范运作》《公司章程》 《独立董事制度》等相关法律、法规、规章的规定和要求，在2023年度工作中， 诚实、勤勉、独立地履行职责，积极出席相关会议，认真审议董事会各项议案， 对公司重大事项发表了独立意见，充分发挥了独立董事及各专业委员会的作用。 现就本人2023年度履行独立董事职责情况汇报如下： 一、出席董事会及股东大会情况 2023年度，公司董事会会议、股东大会的召集召开符合法定程序，重大经营 决策和其他重大事项均按相关规定履行了相关程序，合法有效。 迪安诊断技术集团股份有限公司 独立董事蒋斌先生 2023 年度述职报告 各位股东及股东代表： 报告期内，公司共召开8次董事会，本人应参加3次，均亲自通过现场或通讯 方式出席参与表决，也没有缺席且未委托其他独立董事代为出席应出席会议并行 使表决权的情形。公司股东大会共召开2次会议。 | | | | 出席董事会情况 | | | | --- | --- | --- | --- ...